The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

November 13, 2026

Study Completion Date

November 13, 2026

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

OTHER

XH-S004 20 mg, 40 mg or 60 mg

Administered once per day for 140 days.

OTHER

Placebo

Administered once per day for 140 days.

Trial Locations (1)

China-Japan Friendship Hospital, Beijing

All Listed Sponsors

lead

S-INFINITY Pharmaceuticals Co., Ltd

INDUSTRY